Ibandronate: the First Once-monthly Oral Bisphosphonate for Treatment of Postmenopausal Osteoporosis

Overview

Journal Ther Clin Risk Manag

Publisher Dove Medical Press

Date 2008 Mar 25

PMID 18360577

Citations 4

Authors

Frieder Bauss

Ralph C Schimmer

Affiliations

Soon will be listed here.

Abstract

Osteoporosis is a major healthcare problem that continues growing as the population ages. Sufferers become increasingly susceptible to fractures, which compromise physical and emotional health and increase healthcare costs. Bisphosphonates are the most widely used medicines for the treatment and prevention of postmenopausal osteoporosis. However, therapeutic adherence is suboptimal, meaning that outcomes demonstrated in clinical trials are not realized in the real world. It is anticipated that reducing dosing frequency may facilitate medication intake and thereby improve adherence. Ibandronate is a potent nitrogen-containing bisphosphonate specifically developed for administration with long dose-free intervals. The comprehensive ibandronate preclinical development program has demonstrated dose-dependent improvements or preservation of bone quality and strength. The feasibility of intermittent dosing using the same total dose level as continuous dosing was also confirmed. In postmenopausal osteoporosis, once-monthly oral ibandronate has been shown to be therapeutically equivalent and even superior to daily oral ibandronate, which has demonstrated antifracture efficacy for vertebral and nonvertebral fractures, bone mineral density gains at the spine and hip, and reduction in bone resorption to premenopausal levels. Once-monthly oral ibandronate is also associated with excellent safety and tolerability, and promises to further improve therapeutic adherence to bisphosphonate treatment, thereby enhancing therapeutic outcomes.

Citing Articles

Novel Approaches to Monitor Pharmacokinetics and Metabolism of Gemcitabine-Ibandronate Conjugate in Mice and Dogs.

Klawitter J, Easton M, Karpeisky A, Farrell K, Thamm D, Shokati T Molecules. 2025; 30(2).

PMID: 39860223 PMC: 11767451. DOI: 10.3390/molecules30020354.

Radiolabeling, Quality Control, and Cell Binding Studies of New Tc-Labeled Bisphosphonates: Tc-Ibandronate Sodium.

Ekinci M, Ilem Ozdemir D, Ozgenc E, Gundogdu E, Asikoglu M Turk J Pharm Sci. 2023; 20(2):91-99.

PMID: 37161446 PMC: 10176626. DOI: 10.4274/tjps.galenos.2022.01346.

Impact of -Acetyl Cysteine (NAC) on Tuberculosis (TB) Patients-A Systematic Review.

Mapamba D, Sauli E, Mrema L, Lalashowi J, Magombola D, Buza J Antioxidants (Basel). 2022; 11(11).

PMID: 36421484 PMC: 9687770. DOI: 10.3390/antiox11112298.

Bone physiology, disease and treatment: towards disease system analysis in osteoporosis.

Post T, Cremers S, Kerbusch T, Danhof M Clin Pharmacokinet. 2010; 49(2):89-118.

PMID: 20067335 DOI: 10.2165/11318150-000000000-00000.

Adherence to monthly and weekly oral bisphosphonates in women with osteoporosis.

Cotte F, Fardellone P, Mercier F, Gaudin A, Roux C Osteoporos Int. 2009; 21(1):145-55.

PMID: 19459025 PMC: 2788149. DOI: 10.1007/s00198-009-0930-1.

References

Bauss F, Schenk R, Hort S, Muller-Beckmann B, Sponer G . New model for simulation of fracture repair in full-grown beagle dogs: model characterization and results from a long-term study with ibandronate. J Pharmacol Toxicol Methods. 2004; 50(1):25-34. DOI: 10.1016/j.vascn.2003.11.003. View

Miller P, McClung M, Macovei L, Stakkestad J, Luckey M, Bonvoisin B . Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study. J Bone Miner Res. 2005; 20(8):1315-22. DOI: 10.1359/JBMR.050313. View

Schimmer R, Bauss F . Effect of daily and intermittent use of ibandronate on bone mass and bone turnover in postmenopausal osteoporosis: a review of three phase II studies. Clin Ther. 2003; 25(1):19-34. DOI: 10.1016/s0149-2918(03)90005-1. View

Genant H, Wu C, van Kuijk C, Nevitt M . Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res. 1993; 8(9):1137-48. DOI: 10.1002/jbmr.5650080915. View

Balena R, Toolan B, Shea M, Markatos A, Myers E, Lee S . The effects of 2-year treatment with the aminobisphosphonate alendronate on bone metabolism, bone histomorphometry, and bone strength in ovariectomized nonhuman primates. J Clin Invest. 1993; 92(6):2577-86. PMC: 288453. DOI: 10.1172/JCI116872. View

Harris S, Watts N, Li Z, Chines A, Hanley D, Brown J . Two-year efficacy and tolerability of risedronate once a week for the treatment of women with postmenopausal osteoporosis. Curr Med Res Opin. 2004; 20(5):757-64. DOI: 10.1185/030079904125003566. View

Muhlbauer R, Bauss F, Schenk R, Janner M, Bosies E, Strein K . BM 21.0955, a potent new bisphosphonate to inhibit bone resorption. J Bone Miner Res. 1991; 6(9):1003-11. DOI: 10.1002/jbmr.5650060915. View

Bauss F, Lalla S, Endele R, Hothorn L . Effects of treatment with ibandronate on bone mass, architecture, biomechanical properties, and bone concentration of ibandronate in ovariectomized aged rats. J Rheumatol. 2002; 29(10):2200-8. View

. Osteoporosis prevention, diagnosis, and therapy. NIH Consens Statement. 2001; 17(1):1-45. View

10.

Pillai G, Gieschke R, Goggin T, Jacqmin P, Schimmer R, Steimer J . A semimechanistic and mechanistic population PK-PD model for biomarker response to ibandronate, a new bisphosphonate for the treatment of osteoporosis. Br J Clin Pharmacol. 2004; 58(6):618-31. PMC: 1884644. DOI: 10.1111/j.1365-2125.2004.02224.x. View

11.

Rizzoli R, Greenspan S, Bone 3rd G, Schnitzer T, Watts N, Adami S . Two-year results of once-weekly administration of alendronate 70 mg for the treatment of postmenopausal osteoporosis. J Bone Miner Res. 2002; 17(11):1988-96. DOI: 10.1359/jbmr.2002.17.11.1988. View

12.

Reginster J, Minne H, Sorensen O, Hooper M, Roux C, Brandi M . Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int. 2000; 11(1):83-91. DOI: 10.1007/s001980050010. View

13.

McClung M, Wasnich R, Recker R, Cauley J, Chesnut 3rd C, Ensrud K . Oral daily ibandronate prevents bone loss in early postmenopausal women without osteoporosis. J Bone Miner Res. 2004; 19(1):11-8. DOI: 10.1359/JBMR.0301202. View

14.

Ravn P, Clemmesen B, Riis B, Christiansen C . The effect on bone mass and bone markers of different doses of ibandronate: a new bisphosphonate for prevention and treatment of postmenopausal osteoporosis: a 1-year, randomized, double-blind, placebo-controlled dose-finding study. Bone. 1996; 19(5):527-33. DOI: 10.1016/s8756-3282(96)00229-3. View

15.

Rogers M . New insights into the molecular mechanisms of action of bisphosphonates. Curr Pharm Des. 2003; 9(32):2643-58. DOI: 10.2174/1381612033453640. View

16.

Ettinger B, Black D, Mitlak B, Knickerbocker R, Nickelsen T, Genant H . Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA. 1999; 282(7):637-45. DOI: 10.1001/jama.282.7.637. View

17.

van Beek E, Hoekstra M, Van de Ruit M, Lowik C, Papapoulos S . Structural requirements for bisphosphonate actions in vitro. J Bone Miner Res. 1994; 9(12):1875-82. DOI: 10.1002/jbmr.5650091206. View

18.

Bauss F, Russell R . Ibandronate in osteoporosis: preclinical data and rationale for intermittent dosing. Osteoporos Int. 2004; 15(6):423-33. DOI: 10.1007/s00198-004-1612-7. View

19.

Marcus R, Wong M, Heath 3rd H, Stock J . Antiresorptive treatment of postmenopausal osteoporosis: comparison of study designs and outcomes in large clinical trials with fracture as an endpoint. Endocr Rev. 2002; 23(1):16-37. DOI: 10.1210/edrv.23.1.0453. View

20.

Kalu D . The ovariectomized rat model of postmenopausal bone loss. Bone Miner. 1991; 15(3):175-91. DOI: 10.1016/0169-6009(91)90124-i. View